JUMP REPORT
Avg Daily Volume: 795,234 Market Cap: 812.56M
Sector: Services Short Interest: 14.11
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .03/share REV: 37.99/M
___________________________________________________________
LAST QTR: EPS: .01/share ACTUAL: .04/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .01/share REV: 38.9/M
______________________________________________________
FULL YR: EPS: .13/share REV: 164.68/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
__________________________________________________________________
BEAT/MISS RECORD: –% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -13.59, 9.11, 12.55
EXPECTED JUMP MOVE: 10-15%
——–
*** With market volatility at extremes during the coronavirus pandemic there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before trading.
Links To Latest News and Headlines
January has now been and gone and turned out to be a nice gift for investors. Battered by 2022’s bear, the tech-heavy Nasdaq, in particular, put in an excellent showing, seeing out the month ~11% into the green, in what amounted to its best start to a year since 2001. That signals the appetite for risk is on again and that will be good news for Cathie Wood, the ARK Investment CEO, whose investing style heavily favors disruptors – equities that are naturally positioned at the risky end of the sca
Let’s not try to jinx things by calling attention to this, but Cathie Wood’s on a roll this year. The largest of the exchange-traded funds she runs at Ark Investment Management is up nearly 23% this month. Wood added to her existing stakes in Pinterest (NYSE: PINS), CareDx (NASDAQ: CDNA), and Teladoc Health (NYSE: TDOC) yesterday.
CareDx, Inc ( NASDAQ:CDNA ) shareholders might be concerned after seeing the share price drop 24% in the last quarter…
BRISBANE, Calif., January 26, 2023–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Journal of the American College of Cardiology (JACC): Heart Failure has published a detailed guide1 to help clinicians transition from routine invasive endomyocardial biopsy (EMB) to a less invasive acute rejection monito
BRISBANE, Calif., January 11, 2023–CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced its leading participation and top spot, for the fourth consecutive year, as a Distinguished Founder’s Circle Sponsor for the 23rd Annual ASTS (American Society of Transplant Surgeons) State of the Art Winter Symposium
StockJumpers analysis and trade plans are uploaded generally 1 HOUR BEFORE MARKETS CLOSE (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.